Table 5 Overview of available literature
From: MR-guided stereotactic body radiation therapy for primary cardiac sarcomas
| Primary sarcomas | |||||||
|---|---|---|---|---|---|---|---|
| Publication | Histology | Localization | Number of patients | Dose | Response rate | Survival | Toxicities |
| Aoka 2004 [1] | Primary cardiac angiosarcoma | Right atrium | 1 | 64 Gy/4 Gy carbon-ion radiotherapy, followed by recombinant Interleukin-2 | Locally SD, lung metastases after 4 months | Alive at 1.5 years after treatment | None |
| Bonomo 2015 [17] | Primary cardiac angiosarcoma and malignant melanoma metastasis | Cardiac lesions | 3 |
3 × 8 Gy (80% ID) 5 × 6 Gy (80% ID) |
PR – 2 (PCA) SD – 1 (MM) | Alive at 6 months after treatment, after 8 months 1 patient died (lung metastasis) | None |
| Gabani 2019 [13] | Primary cardiac angiosarcoma | Right atrium (7.3 cm) | 1 | 5 × 6 Gy daily, concurrent paclitaxel (80 mg/m2) weekly | After 6 weeks: ipilimumab/nivolumab → PR: 4.1 cm but progression of pulmonary metastasis | Alive at 6 months after treatment | Esophagitis |
| Isambert 2013 [3] | Primary cardiac sarcoma | Cardiac lesions | 124 of which 24 were treated with radiotherapy: 18 adjuvant and 6 definitive | Median dose 50 Gy (range 10–64 Gy). 23 followed by chemotherapy | Benefit in PFS | mOS 17.2 months (all), better survival with radiotherapy (HR 0.54, inivariate; HR 0.62 multivariate analysis) | n.a. |
| Nakamura-Horigome 2008 [18] | Primary cardiac angiosarcoma | Right atrium, right ventricular wall | 1 | 42 Gy/2 Gy Simultaneous radiochemotherapy with docetaxel & 12 months low dose docetaxel | SD | Alive at 12 months after treatment | Esophagitis |
| Pötter 1989 [19] | Primary cardiac angiosarcoma | Right atrium | 1 | 40 Gy/1.8 Gy whole heart/mediastinum, boost with 60 Gy to the right atrium, simultaneous radiochemotherapy | Macroscopic no tumor at autopsy | OS 15 months, died of progressive brain metastases | None |
| Soltys 2008 [20] | Pulmonary artery intimal sarcoma | Left pulmonary artery | 1 | 3 × 11 Gy (79% ID) | Improvement of dyspnea | Died 10 weeks after SBRT due to metastatic progression | None |